Compound guides, documentation and careful readings of what the evidence does—and does not—show.
24 articles · Owner-provided research content · No expert review claimed
Documentation · 5 min readLearn how to trace a Canadian trial from Health Canada's portal to its registry and published paper, compare outcomes, and separate trial from product authorization.
Read articleUnderstand peptide adsorption to sample containers, its limits in laboratory evidence, and the records that help distinguish calculated concentration from recovery.
Read articleA practical pre-purchase checklist for comparing research-material listings, records and identifiers.
Read articleHow to read a certificate of analysis without treating one result as proof of everything.
Read articleA documentation-first storage plan that keeps product-specific instructions in control.
Read articleHow to use Health Canada’s Drug Product Database without confusing an ingredient match with product authorization.
Read articleA side-by-side framework for comparing what a listing actually says before comparing price.
Read articleA plain-language guide to BPC-157 as an experimental peptide studied in tissue-repair models, and the limits of that work.
Read articleWhat mouse wound-healing research on thymosin beta-4 shows, and why a TB-500 label needs supplier confirmation.
Read articleWhat published retatrutide research reported, why it is informally called GLP-3, and why GLP-3 is not a receptor name.
Read articleWhat the CJC-1295 and ipamorelin literature reports separately, and what a 10 mg blend listing leaves unspecified.
Read articleHow to read a BPC-157 and TB-500 blend listing when the cited research examined each component separately.
Read articleWhat the 2007 tesamorelin trial measured, why visceral fat is not general weight loss, and what that excludes.
Read articleHow official labelling describes semaglutide’s GLP-1 receptor mechanism, what STEP 1 measured, and the limits of both.
Read articleWhat US bremelanotide labelling states about mechanism, indication and adverse effects — and what it excludes.
Read articleWhat the receptor names in metabolic peptide research refer to, and why the informal GLP-3 name for retatrutide is not a receptor name.
Read articleA tiering framework for peptide literature, with worked examples of what each study type can and cannot support.
Read articleHow to reason about a multi-component listing when the published studies examined the components separately.
Read articleFour questions that turn a study abstract into a sentence you can actually defend.
Read articleA worksheet for checking whether a certificate of analysis genuinely belongs to the vial in front of you, and what verification cannot settle.
Read articleWhy a purity percentage, a content figure and an activity result answer separate questions — with worked illustrative examples showing how they can disagree.
Read articleA repeatable five-step audit for tracing a peptide claim back to its evidence, with worked illustrative examples of how claims drift.
Read articleA reusable record layout for keeping the three descriptions of the same material — listing, label and report — aligned, with unknowns recorded as unknown.
Read articleHow milligrams per millilitre is calculated, how a target sample amount becomes a volume, and which assumptions the arithmetic does not make.
Read article